This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Layoffs Continue to Mount

NOVARTIS

Novartis (NOVN) is cutting 1,960 jobs in the U.S. The announcement comes as the company anticipates losing patent exclusivity on the drug Diovan in September 2012. The cost cutting measure also follows disappointing trials of Tekturna, another hypertension medication made by Novartis.

The company terminated trials of Tekturna after the pill caused complications for diabetes patients. Analysts say that growth will likely struggle in light of the charges the company is taking on Tekturna and generic competition for Diovan.

Basel, Switzerland-based Novartis has been cutting expenses since Joe Jimenez became chief executive officer in February 2010. The latest layoffs are the third time Novartis has announced job cuts in the past 14 months. The company announced 1,400 layoffs in November 2010 and 200 more in October 2011.

Of the 1,960 job cuts planned for the current year, 1,630 will be from the company's sales division. The reductions will save the company an estimated $450 million by 2013.

16 of 20

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ATV $1.46 0.00%
AVP $6.88 0.00%
IBM $170.13 0.00%
HP $72.66 0.00%
PEP $95.79 0.00%

Markets

DOW 18,041.54 -190.48 -1.04%
S&P 500 2,104.20 -21.86 -1.03%
NASDAQ 5,032.7510 -56.6110 -1.11%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs